Tempus AI to buy Personalis for $1.5 billion to scale AI cancer monitoring

Tempus AI agreed to acquire cancer testing firm Personalis for about $1.5 billion, folding its molecular residual disease technology into the Tempus multimodal data and AI precision oncology platform.